Inhibikase Therapeutics Inc
inhibikase.comInhibikase Therapeutics (NASDAQ: IKT) is a clinical-stage biopharmaceutical company developing protein kinase inhibitor drug candidates for neurodegeneration and cardiovascular disease. The company generates no product revenue and funds operations through equity issuances, including common stock, pre-funded warrants, and warrants. Inhibikase was founded in September 2008 as a Georgia limited liability company, completed its IPO in 2020, and is listed on Nasdaq under the symbol IKT. Its lead program as of the 10-K filed March 26, 2026 is IKT-001, focused on pulmonary arterial hypertension (PAH), after the company paused development of risvodetinib in January 2025. In February 2025, the company acquired CorHepta Pharmaceuticals, Inc. to expand its pipeline. A Phase 2b/3 PAH study, IMPROVE-PAH, is under way, with contracted CRO costs of approximately $25.5 million and clinical supply commitments of approximately $6.3 million remaining as of December 31, 2025.
Products & Services
IKT-001: lead kinase inhibitor candidate in Phase 2b/3 development for pulmonary arterial hypertension (IMPROVE-PAH study). Risvodetinib: kinase inhibitor candidate whose development was paused in January 2025. Pipeline expanded via acquisition of CorHepta Pharmaceuticals in February 2025. Original platform based on protein kinase inhibitors initially developed for bacterial and viral infectious diseases, later redirected toward neurodegeneration and cardiovascular disease.
Revenue Model
Pre-revenue clinical-stage company. Operations are financed by equity capital raises, including issuances of common stock, pre-funded warrants, and warrants. No product sales or licensing revenue are disclosed in the filing excerpts.
Customers & Markets
No commercial customers. End markets targeted are pulmonary arterial hypertension and neurodegeneration. Drug candidates are in clinical development and have not received regulatory approval as of the filing date.
Geographic Exposure
Headquartered in the United States. Clinical and regulatory activities directed at the FDA. No international commercial operations disclosed in the filing excerpts.
Financial Snapshot
Loading...
